In a significant development for oncology and medical technology, Alpha Tau Medical has officially announced the completion of patient enrollment for its ReSTART pivotal trial. This clinical study is designed to evaluate the safety and efficacy of the company’s proprietary Alpha Diffusing Alpha-emitters Radiation Therapy (DaRT) in patients suffering from recurrent cutaneous squamous cell carcinoma (cSCC). As the first Alpha Tau pivotal trial to reach full enrollment in the United States, this achievement represents a major step forward in the company’s quest for pre-market approval (PMA) from the US Food and Drug Administration (FDA).
The Clinical Challenge: Addressing Recurrent cSCC
Cutaneous squamous cell carcinoma is the second most common form of skin cancer. While the majority of cases are treatable with standard surgical excision or radiation, a subset of patients faces recurring, aggressive disease that proves resistant to first-line therapies. For these individuals, options are often limited, and the prognosis can be challenging.
The ReSTART trial specifically targets this patient population, focusing on 88 individuals with biopsy-confirmed recurrent cSCC who have exhausted standard-of-care options. By providing a novel, localized treatment approach, Alpha Tau Medical aims to address a significant unmet medical need in oncology.
Chronology of Development: From Concept to Pivotal Trial
The journey of Alpha DaRT from a theoretical treatment model to a late-stage clinical candidate has been characterized by steady, methodical progress across international borders.
- Early Clinical Foundations: The technology was initially piloted in international markets, including Canada, France, Italy, and Israel. These early studies provided the proof-of-concept data required to demonstrate that intratumoral delivery of alpha radiation could effectively target tumor cells while sparing surrounding healthy tissue.
- US Entry and Regulatory Engagement: As the company expanded its clinical footprint, it initiated high-level discussions with the FDA. Recognizing the potential of the technology, the FDA granted Alpha DaRT “Breakthrough Device” designation, an important status intended to expedite the development and review of medical devices that provide more effective treatment for life-threatening or irreversibly debilitating conditions.
- The IDE Milestone: In September 2024, the FDA granted approval for Alpha Tau’s Investigational Device Exemption (IDE) application. This authorization served as the green light for the company to begin the ReSTART trial, the pivotal study required to support a formal PMA submission.
- Enrollment Completion (May 2026): After months of multi-center coordination, the company reached its target of 88 enrolled patients, successfully transitioning the study from the recruitment phase to the critical data maturation and follow-up phase.
Technical Overview: How Alpha DaRT Works
Unlike traditional external beam radiation therapy, which targets tumors from outside the body and often carries the risk of damaging nearby healthy tissue, Alpha DaRT operates on a different principle.
The therapy involves the intratumoral delivery of radioactive seeds. These seeds release alpha-emitting atoms that diffuse throughout the tumor, delivering a potent, concentrated dose of radiation directly to the cancerous cells. Because alpha particles have a very short range of travel, they provide intense localized damage to the DNA of the tumor, while the surrounding healthy tissue remains largely unaffected. This high-precision approach is particularly beneficial for recurring skin cancers, where the tissue may have already been compromised by previous surgeries or radiation treatments.
Study Design and Supporting Data
The ReSTART trial is a single-arm, open-label, multi-center study. By utilizing an open-label design, researchers and clinicians can closely monitor the progress of all 88 patients, ensuring a comprehensive collection of safety and efficacy data.
Co-Primary Endpoints
The success of the trial will be measured primarily through two critical metrics:
- Objective Response Rate (ORR): This is calculated based on the confirmed best overall response observed in patients during the treatment cycle. It provides a snapshot of how effectively the therapy shrinks or eliminates the tumor.
- Duration of Response (DOR): Measured at six months from the initial response, this endpoint evaluates the durability of the treatment effect. For patients with recurrent cancer, the ability to maintain a response over time is just as important as the initial tumor reduction.
Secondary Endpoints
Beyond the co-primary measures, the study is tracking several secondary indicators to provide a holistic view of patient outcomes:
- Progression-Free Survival (PFS): The duration of time the patient lives without the disease worsening.
- Overall Survival (OS): Measured at one year, providing long-term perspective on the therapy’s impact on patient longevity.
- Local Control: The ability of the therapy to prevent recurrence at the specific site of the treated tumor.
- Quality of Life (QoL): A vital component for cancer patients, this measures how the treatment impacts the patient’s daily functioning and physical well-being.
Official Perspectives: Leadership on the Milestone
Uzi Sofer, CEO of Alpha Tau Medical, described the completion of enrollment as a "watershed moment" for the organization.
"Skin cancer was the very first clinical application of Alpha DaRT, and it has served as the cornerstone of our entire clinical development strategy," Sofer noted. "The years of evidence we have generated across multiple countries and numerous patients have consistently demonstrated the strength of our intratumoral radiotherapeutic approach. This milestone provides the foundation not only for this pivotal study, but also for our expanding clinical programs in additional indications."
The company’s leadership remains optimistic that the data gathered from the 88-patient cohort will be robust enough to convince regulators of the therapy’s safety profile and clinical utility.
Implications for the Future of Oncology
The completion of the ReSTART trial carries significant implications for the medical device industry and for patients with difficult-to-treat skin cancers.
Regulatory Implications
If the ReSTART trial meets its endpoints, Alpha Tau Medical will move toward a PMA submission. A successful approval would solidify Alpha DaRT as a recognized standard of care for recurrent cSCC in the United States. Furthermore, the regulatory pathway established by this trial serves as a roadmap for future applications of the technology, potentially in cancers of the head, neck, and other regions where localized radiation is preferable to surgery or systemic chemotherapy.
Clinical Impact
For clinicians, the availability of a device like Alpha DaRT would offer a much-needed alternative. When patients with cSCC fail first-line therapy, they often face disfiguring surgeries or systemic treatments with significant side effects. A localized, high-potency radiotherapy tool allows for a more patient-centric approach, potentially improving both clinical outcomes and patient quality of life.
Market and Industry Dynamics
The success of Alpha Tau Medical reflects a broader trend in the oncology market: the move toward highly specialized, localized delivery systems. As the company prepares for the data maturation phase, industry observers will be watching closely to see if the "real-world" performance of Alpha DaRT matches the promising results seen in its earlier international studies.
Next Steps
With the enrollment phase closed, the focus of the ReSTART trial shifts to the data follow-up phase. The researchers will continue to monitor the patient cohort to collect the necessary data for the primary and secondary endpoints.
The maturation of this data will be a multi-month process, during which the clinical team will compile the final results for submission to the FDA. Should the results prove statistically significant and clinically meaningful, it will pave the way for a transformative shift in how recurrent cSCC is managed in clinical settings.
For the medical community, the ReSTART trial stands as a testament to the importance of specialized radiotherapy in the modern oncology toolkit. By focusing on patients who have run out of options, Alpha Tau Medical is not only testing a device—it is potentially opening a new door for those most in need of innovation.
About the Author
